Pankaine Glucose (Bupivacaine Hydrochloride, Anhydrous)

Bupivacaine Hydrochloride blocks voltage‑gated sodium channels on neuronal membranes. By preventing sodium influx during depolarization, it stops the initiation and propagation of nerve impulses. This interruption of electrical signaling results in loss of sensation and motor function in the area supplied by the blocked nerves, producing a reliable and extended anesthetic effect.

The specific intrathecal dose of Pankaine Glucose is determined by the prescribing clinician based on the type of procedure, patient weight, age, and overall health status. Dosing guidelines are provided in the product’s prescribing information, and the prescriber tailors the amount to achieve the desired anesthetic depth while minimizing risk.

Safety data for Bupivacaine Hydrochloride during pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians must evaluate each case individually, and it is generally avoided in the first trimester and during breastfeeding unless absolutely necessary.

To request Pankaine Glucose, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides a quotation, confirms availability, arranges shipping (including cold‑chain if needed), and handles all import documentation.

Compared with shorter‑acting agents such as lidocaine, Bupivacaine Hydrochloride offers a longer duration of sensory and motor block, making it suitable for prolonged surgeries and postoperative analgesia. However, its higher potency also carries a greater risk of cardiotoxicity, so careful dosing and monitoring are essential. Choice of agent depends on the required block length, patient risk profile, and procedural considerations.

Pankaine Glucose should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the product from direct sunlight, moisture and extreme temperature fluctuations. Before use, inspect the solution for particulate matter or discoloration, and handle it with aseptic technique to maintain sterility. Follow local regulations for disposal of any unused material.

Pankaine Glucose is administered by a qualified clinician via a sterile intrathecal injection into the subarachnoid space, typically at the lumbar level. The procedure is performed under aseptic conditions using a spinal needle. Dosage is calculated by the prescriber, and the patient is monitored continuously for cardiovascular and respiratory stability throughout the anesthetic period.

The most serious adverse events include cardiac toxicity such as arrhythmias or cardiac arrest, central nervous system toxicity manifesting as seizures, severe respiratory depression requiring ventilatory support, and anaphylactic reactions. These risks are heightened by accidental intravascular injection or excessive dosing. Immediate recognition and supportive measures are critical to mitigate potential harm.

Pankaine Glucose is contraindicated in patients with known hypersensitivity to amide‑type local anesthetics, those with severe spinal canal pathology, or individuals with significant cardiac conduction disorders. Caution is also advised for patients with uncontrolled epilepsy, severe hepatic impairment, or those receiving other agents that may potentiate its cardiotoxic or neurotoxic effects. The decision to use the drug must be made by a qualified healthcare professional after thorough assessment.